A 49-year-old man with acute myeloid leukemia developed fever and hypoxemia while undergoing induction chemotherapy. He had been severely neutropenic (absolute neutrophil count < 500 cells/μL) for 16 days and was not on antifungal prophylaxis. Contrast-enhanced computed tomography of the chest showed a focus of ground-glass opacity surrounded by a 1.5 cm rim of consolidation, known as the reverse halo sign (RHS) (Fig. 1). Polymerase chain reaction testing of bronchial washings detected Rhizopus microsporus DNA, consistent with invasive pulmonary mucormycosis (IPM).
Figure 1.
The reverse halo sign. Contrast-enhanced computed tomography of the chest showing a focal lung lesion with central ground-glass opacity (black arrow) surrounded by dense consolidation (yellow arrow), known as the reverse halo sign.
The RHS has been identified in numerous noninfectious diseases.1,2 However, in an immunocompromised host, it is presumed to indicate an invasive fungal pneumonia, particularly when the rim of consolidation is thicker than 1.0 cm.3–6 The RHS occurs more often in IPM than invasive pulmonary aspergillosis (IPA) and strongly predicts IPM in immunocompromised hosts.3,4,7–9 Therefore, the presence of the RHS in an immunocompromised host should prompt clinicians to consider initiating liposomal amphotericin B (the preferred initial treatment of IPM) instead of voriconazole (the preferred treatment for IPA, but without activity against IPM).10,11 Recognizing the clinical significance of the RHS may improve patient outcomes by allowing for early initiation of appropriate antifungals and timely surgical consultation to consider resection.11,12
Declarations
Conflict of Interest
The authors declare that they do not have a conflict of interest.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Voloudaki AE, Bouros DE, Froudarakis ME, Datseris GE, Apostolaki EG, Gourtsoyiannis NC. Crescentic and ring-shaped opacities. CT features in two cases of bronchiolitis obliterans organizing pneumonia (BOOP) Acta Radiol. 1996;37(6):889–892. doi: 10.1177/02841851960373P289. [DOI] [PubMed] [Google Scholar]
- 2.Maturu VN, Agarwal R. Reversed halo sign: a systematic review. Respir Care. 2014;59(9):1440–1449. doi: 10.4187/respcare.03020. [DOI] [PubMed] [Google Scholar]
- 3.Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52(9):1144–1155. doi: 10.1093/cid/cir122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008;46(11):1733–1737. doi: 10.1086/587991. [DOI] [PubMed] [Google Scholar]
- 5.Marchiori E, Marom EM, Zanetti G, Hochhegger B, Irion KL, Godoy MCB. Reversed halo sign in invasive fungal infections. Chest. 2012;142(6):1469-1473. 10.1378/chest.12-0114 [DOI] [PubMed]
- 6.Marchiori E, Hochhegger B, Zanetti G. Importance of the reversed halo sign for diagnosis of mucormycosis. Lancet Infect Dis. 2020;20(5):538. doi: 10.1016/S1473-3099(20)30266-8. [DOI] [PubMed] [Google Scholar]
- 7.Caillot D, Valot S, Lafon I, et al. Is it time to include CT “reverse halo sign” and qPCR targeting Mucorales in serum to EORTC-MSG criteria for the diagnosis of pulmonary mucormycosis in leukemia patients? Open Forum Infect Dis. 2016;3(4):ofw190. 10.1093/ofid/ofw190 [DOI] [PMC free article] [PubMed]
- 8.Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–66. doi: 10.1086/430710. [DOI] [PubMed] [Google Scholar]
- 9.Jung J, Kim MY, Lee HJ, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015;21(7):684.e11–18. doi: 10.1016/j.cmi.2015.03.019. [DOI] [PubMed] [Google Scholar]
- 10.Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20(3):581–607. doi: 10.1016/j.idc.2006.06.003. [DOI] [PubMed] [Google Scholar]
- 11.Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–509. doi: 10.1086/590004. [DOI] [PubMed] [Google Scholar]
- 12.Multani A, Reveron-Thornton R, Garvert DW, Gomez CA, Montoya JG, Lui NS. Cut it out! Thoracic surgeon’s approach to pulmonary mucormycosis and the role of surgical resection in survival. Mycoses. 2019;62(10):893–907. doi: 10.1111/myc.12954. [DOI] [PubMed] [Google Scholar]